Physician profile
Frank Criddle
NPI 1447279526
$4,260.44
in general payments reported to CMS, 2019-2025
22 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $386 · 2021: $682 · 2022: $723 · 2023: $662 · 2024: $791 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,477.07 | 2019-2024 | Xarelto |
| Pfizer INC. | $634.62 | 2019-2025 | |
| Abbvie INC. | $432.28 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| E.R. Squibb & Sons, L.L.C. | $297.88 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.62 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $186.48 | 2019-2024 | Dificid, Zerbaxa |
| Novo Nordisk INC | $158.46 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.55 | 2023-2025 | Xifaxan |
| Gilead Sciences, INC. | $106.45 | 2023-2024 | Veklury |
| Philips North America LLC | $103.09 | 2019-2024 | (Cm9) Amb Mon & Diag Und |
| Alexion Pharmaceuticals, INC. | $100.33 | 2023-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $93.95 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $66.97 | 2019 | |
| Viatris Specialty LLC | $56.10 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $44.94 | 2023 | Terlivaz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.18 | 2019 | |
| Amgen INC. | $34.53 | 2024 | Evenity, Prolia |
| Inari Medical, INC. | $20.58 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $17.97 | 2024 | Cleviprex |
| Currax Pharmaceuticals LLC | $17.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.19 | 2019 | |
| Boston Scientific Corporation | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Criddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.